PUBLISHER: IMARC | PRODUCT CODE: 1722719
PUBLISHER: IMARC | PRODUCT CODE: 1722719
The global interventional cardiology devices market size reached USD 24.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 43.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.53% during 2025-2033. The rising prevalence of cardiovascular diseases, aging population, ongoing technological advancements, and increasing shift towards minimally invasive procedures are primarily driving the market's growth.
Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting. Some of the commonly used devices include angioplasty balloons, stents, mitral, pulmonary and tricuspid valves, catheters, plaque modification and hemodynamic flow alteration devices. Along with this, guidewires, vascular closure and hemostasis devices and introducer sheaths are also utilized. These tools and devices are widely used for medical procedures, such as coronary artery bypass grafting (CABG), trans-myocardial laser revascularization (TMR), arrhythmia treatment, aneurysm repair, open-heart, off-pump heart and minimally invasive (MI) heart surgeries. They are also used for other procedures, such as atherectomy, embolic protection and percutaneous valve repair.
The increasing prevalence of diabetes, hypertension and cardiovascular disorders, such as coronary artery disease (CAD, is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Interventional cardiology and embolic protection devices are widely used to capture embolic debris to ensure continuous blood flow and preventing blockages. Additionally, the development of innovative bioabsorbable and drug-eluting stents, pacemakers and drug-coated mesh tubes is acting as another growth-inducing factor. In line with this, the increasing utilization of advanced imaging solutions, such as intravenous ultrasound (IVUS), fractional flow reserve (FFR) and optical coherence tomography (OCT) for early diagnosis and timely treatment of cardiovascular ailments, is also contributing to the growth of the market. Other factors, including rising healthcare expenditure capacities of the masses, along with extensive improvements in the medical infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Alvimedica, B. Braun Melsungen AG, Biosensors International Group Ltd. (Bluesail Medical Co. Ltd.), BIOTRONIK Inc., Boston Scientific Corporation, Cook Group Incorporated, ENDOCOR GmbH, Koninklijke Philips N.V., Medinol Ltd., Medtronic plc and Terumo Corporation.